Compare · head to head
Exelixis vs Incyte
Exelixis ranks higher overall — 360 rank 96 vs 95.
Incyte leads on Value (70 vs 65) and Growth (56 vs 49). Exelixis leads on Quality (82 vs 68). The two are close on Safety and Sentiment.
Ranks as of 2026-06-12 · 1–100 vs true peers. Higher is better.
| Compare | ||
|---|---|---|
| Profile | ||
| Country | USA | USA |
| Sector | Health Care | Health Care |
| Industry | Biotechnology | Biotechnology |
| Size | Large | Large |
| ISIN | US30161Q1040 | US45337C1027 |
| Last update | 2026-04-02 | 2026-04-02 |
| History | ||
| 360 (V1) since 2023 | — | |
| Ranks | ||
| 360 | 96 | 95 |
| Value | 65 | 70 |
| Quality | 82 | 68 |
| Growth | 49 | 56 |
| Safety | 64 | 68 |
| Sentiment | 46 | 44 |
| Quality details | ||
| Profitability | 96 | 84 |
| Cash Truth | 68 | 51 |
Exelixis vs Coherus OncologyExelixis vs Janux TherapeuticsExelixis vs IDEAYA BiosciencesExelixis vs Rigel PharmaceuticalsAdd a third stock →
Full analyses: Exelixis · Incyte
Make Sense of the Ranks
Every rank runs 1–100 against true peers. Higher is always better.
360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100